ReviewTransgenic research2023
Regulatory and policy considerations for the implementation of gene drive-modified mosquitoes to prevent malaria transmission.
Review in Transgenic research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 27 citations in OpenAlex.
- The architecture of computational antiviralism: a multi-scale framework from molecular targeting to viral ecosystem engineering.Molecular diversity · 2026Review
- Malaria: a review on its current epidemiological status and management strategies.Malaria journal · 2026Review
- Exploratory conversations with biodiversity-oriented civil society groups on the potential applications of gene drive-modified mosquitoes for malaria control in Tanzania.Transgenic research · 2026Article
- "Have Scientists Done Enough?" Community Perspectives on Gene Drive-Modified Mosquitoes for Malaria Control in Northern Uganda: A Mixed-Methods Study.Journal of epidemiology and global health · 2025Article
- Is Gene Drive Research Losing Traction?The American journal of tropical medicine and hygiene · 2025Article
- A suppression-modification gene drive for malaria control targeting the ultra-conserved RNA gene mir-184.Nature communications · 2025Article
- Current trends in application of CRISPR/Cas9 in gene editing and diagnostics in Neglected tropical diseases (NTDs).Molecular biology reports · 2025Review
- Integrating malaria vaccine and CRISPR/Cas9 gene drive: a comprehensive strategy for accelerated malaria eradication.Malaria journal · 2025Review
- Procedural legitimacy: co-developing a community agreement model for genetic approaches research to malaria control in Africa.Malaria journal · 2024Article
- Post-release monitoring pathway for the deployment of gene drive-modified mosquitoes for malaria control in Africa.Malaria journal · 2024Article
- Generating prophylactic immunity against arboviruses in vertebrates and invertebrates.Nature reviews. Immunology · 2024Review
- The behaviour of adult Anopheles gambiae, sub-Saharan Africa's principal malaria vector, and its relevance to malaria control: a review.Malaria journal · 2024Review
- Review
- Article
- Review
- Anti-CRISPR Anopheles mosquitoes inhibit gene drive spread under challenging behavioural conditions in large cages.Nature communications · 2024Article
- Navigating biosafety regulatory frameworks for genetic engineering in Africa: a focus on genome editing and gene drive technologies.Frontiers in bioengineering and biotechnology · 2024Article
- The Promise and Challenge of Genetic Biocontrol Approaches for Malaria Elimination.Tropical medicine and infectious disease · 2023Review
- Requirements for market entry of gene drive-modified mosquitoes for control of vector-borne diseases: analogies to other biologic and biotechnology products.Frontiers in bioengineering and biotechnology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gene drive-modified mosquitoes (GDMMs) are being developed as possible new tools to prevent transmission of malaria and other mosquito-borne diseases. To date no GDMMs have yet undergone field testing. This early stage is an opportune time for developers, supporters, and possible users to begin to consider the potential regulatory requirements for eventual implementation of these technologies in national or regional public health programs, especially as some of the practical implications of these requirements may take considerable planning, time and coordination to address. Several currently unresolved regulatory questions pertinent to the implementation of GDMMs are examined, including: how the product will be defined; what the registration/approval process will be for placing new GDMM products on the market; how the potential for transboundary movement of GDMMs can be addressed; and what role might be played by existing multinational bodies and agreements in authorization decisions. Regulation and policies applied for registration of other genetically modified organisms or other living mosquito products are assessed for relevance to the use case of GDMMs to prevent malaria in Africa. Multiple national authorities are likely to be involved in decision-making, according to existing laws in place within each country for certain product classes. Requirements under the Cartagena Protocol on Biodiversity will be considered relevant in most countries, as may existing regulatory frameworks for conventional pesticide, medical, and biocontrol products. Experience suggests that standard regulatory processes, evidence requirements, and liability laws differ from country to country. Regional mechanisms will be useful to address some of the important challenges.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.